Toward the design of cannabinoid CB1 receptor inverse agonists and neutral antagonists

@article{Reggio2009TowardTD,
  title={Toward the design of cannabinoid CB1 receptor inverse agonists and neutral antagonists},
  author={Patricia H. Reggio},
  journal={Drug Development Research},
  year={2009},
  volume={70}
}
  • P. Reggio
  • Published 1 December 2009
  • Biology, Chemistry
  • Drug Development Research
The cannabinoid CB1 receptor belongs to Class A of the G‐protein‐coupled receptor (GPCR) family. The high constitutive activity of CB1 facilitates inverse agonism at this receptor, and CB1 inverse agonists/antagonists have recently been considered for the treatment of obesity and metabolic syndrome. GPCRs are assumed to have a common topology and to share a common molecular activation mechanism involving their intracellular domains. However, each individual receptor will also have a molecular… 
Ligand-specific homology modeling of human cannabinoid (CB1) receptor.
Exploring the Ligand Efficacy of Cannabinoid Receptor 1 (CB1) using Molecular Dynamics Simulations
TLDR
These findings shed light on the understanding of different efficacy profiles of ligand by analyzing the structural behaviors of intact CB1 structures and the binding energies of ligands, thereby yielding insights that are useful for the design of new potent CB1 drugs.
Metabolic Profiling of CB1 Neutral Antagonists.
What Role Does the Endocannabinoid System Play in the Pathogenesis of Obesity?
TLDR
The role of the ECS and the impact of genetic factors on endocannabinoid system modulation in the pathogenesis of obesity is explained and the search for potential new targets for health assessment, treatment, and the development of possible therapies in obesity is emphasized.
Synthesis of Dibenzofurans via a Palladium Catalyzed Oxidative Ring Closure Reaction
This Honors Thesis-Unrestricted is protected by copyright and/or related rights. It has been brought to you by ScholarWorks@UNO with permission from the rights-holder(s). You are free to use this

References

SHOWING 1-10 OF 100 REFERENCES
Homology model of the CB1 cannabinoid receptor: Sites critical for nonclassical cannabinoid agonist interaction
TLDR
The present study represents one of the first attempts to construct a homology model of the CB1 cannabinoid receptor based upon the published bovine rhodopsin x‐ray crystal structure and to elucidate the putative ligand binding site for nonclassical cannabinoid agonists.
Hemopressin is an inverse agonist of CB1 cannabinoid receptors
TLDR
The identification of hemopressin (PVNFKFLSH) as a peptide ligand that selectively binds CB1 cannabinoid receptors is identified and it is found that it exhibits antinociceptive effects when administered by either intrathecal, intraplantar, or oral routes, underscoring hemopressingin's therapeutic potential.
CB1 cannabinoid antagonists: structure-activity relationships and potential therapeutic applications.
TLDR
The current review will mainly focus on the structure-activity relationships that have been established for antagonists/inverse agonists that bind to the CB1 cannabinoid receptors and on their therapeutic applications.
Relationships Between Ligand Affinities for the Cerebellar Cannabinoid Receptor CB1 and the Induction of GDP/GTP Exchange
TLDR
It is demonstrated that theCB1 receptor of the cerebellum can assume an active conformation in the absence of agonist and that the variability in efficacy among CB1 receptor agonists can be explained by the relative affinities of these ligands for the CB1 receptors in the active and inactive states.
WIN55212-2 Docking to the CB1 Cannabinoid Receptor and Multiple Pathways for Conformational Induction
TLDR
It appears that aromatic-aromatic interactions are important not only for the binding of 1 but also for inducing receptor conformational change in the CB1 receptor.
Negative antagonists promote an inactive conformation of the beta 2-adrenergic receptor.
TLDR
It is shown that, of several beta-adrenergic receptor-blocking drugs tested, only two, ICI 118551 and betaxolol, inhibit the basal signaling activity of the beta 2-adRenergic receptor, thus acting as negative antagonists.
LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation.
TLDR
This compound blocked WIN 55212-2-mediated inhibition of N-type calcium channels and activation of inwardly rectifying potassium channels in N18 and AtT-20-CB2 cells, respectively.
...
...